GLENMARK PHARMACEUTICALS
GLENMARKVerifiedGLENMARK PHARMACEUTICALS is a publicly traded security listed on the NSE/BSE exchange.
Stock Snapshot & Key Numbers — GLENMARK PHARMACEUTICALS
Verified Daily CloseOfficial closing price, 1-year price range, valuation multiples, and market value from exchange records.
GLENMARK PHARMACEUTICALS (GLENMARK) is a Indian equity security listed on the NSE/BSE with ISIN BSE:532296. As of the last recorded market session on Close on 16 Oct 2026, the stock closed at ₹2226.70, recording a -23.80 (-1.06%) decline from its previous close of ₹2250.50. Over the trailing 52-week trading cycle, GLENMARK has traded between a 52-week low of ₹1810.40 and a 52-week high of ₹2515.00, establishing its annual trading channel. In historical performance, GLENMARK PHARMACEUTICALS has gained 19.43% over the past 1 year. Period returns across standard measurement intervals include: 1-week: -2.89%, 1-month: -7.61%, 6-month: -1.01%, 1-year: +19.43%, 3-year: +179.11%, 5-year: +329.04%. Daily reported trading volume reached 6,95,427 equity shares. On key valuation multiples as of 11 Oct 2026, the company trades at a trailing price-to-earnings (P/E) multiple of 36.0x and a price-to-book (P/B) ratio of 6.2x, with a trailing dividend yield of 0.11%. Its market capitalization stands at ₹64,714.12 Cr. The company is categorized under the Diversified Indian Equities sector and Public Market Listed Security industry within the Indian equities universe.
Price Chart
Trading Multiples & Ranges
Price boundaries and liquidity distribution.
Past Price Win/Loss Odds (1-Week, 1-Month, 3-Month)
How often this stock rose, stayed flat, or fell over past 21-day holding periods (based on historical data, not a future prediction).
How Outside Factors Affect This Stock (Market, Crude Oil & Currency)
How closely this stock moved with the broader market index, crude oil, and the exchange rate over the past year.
| Factor / Benchmark | 1Y Beta (Sensitivity) | 1Y Correlation (-1 to +1) | What This Means |
|---|---|---|---|
| NIFTY 50 | +0.88 | +0.43 | Trailing 1Y historical sensitivity: a 1% move in NIFTY 50 coincided with a +0.88% co-movement (correlation: 0.43). Descriptive historical relationship, not predictive. |
| USD / INR | -0.21 | -0.06 | Trailing 1Y historical sensitivity: a 1% move in USD / INR coincided with a -0.21% co-movement (correlation: -0.06). Descriptive historical relationship, not predictive. |
| Brent Crude Oil | -0.04 | -0.08 | Trailing 1Y historical sensitivity: a 1% move in Brent Crude Oil coincided with a -0.04% co-movement (correlation: -0.08). Descriptive historical relationship, not predictive. |
| US 10Y Treasury Yield | +0.08 | +0.04 | Trailing 1Y historical sensitivity: a 1% move in US 10Y Treasury Yield coincided with a +0.08% co-movement (correlation: 0.04). Descriptive historical relationship, not predictive. |
How to read Beta & Correlation ( Beta > 1 = wider swings than market; < 1 = calmer )▾
Sensitivities measure historical 1-year regression beta and correlation across paired daily trading sessions over the past 252 trading days. Past relationships can shift over time and do not guarantee future co-movement.
Trailing Returns Breakdown
Calendar-aligned historical percentage performance across standard market windows.
| Period | Start Price | Current Price | Return (%) |
|---|---|---|---|
| 1 Week | ₹2,293.00 | ₹2,226.70 | -2.89% |
| 15 Days | ₹2,331.00 | ₹2,226.70 | -4.47% |
| 1 Month | ₹2,410.00 | ₹2,226.70 | -7.61% |
| 3 Months | ₹2,286.90 | ₹2,226.70 | -2.63% |
| 6 Months | ₹2,249.50 | ₹2,226.70 | -1.01% |
| 1 Year | ₹1,864.40 | ₹2,226.70 | +19.43% |
| 3 Years | ₹797.80 | ₹2,226.70 | +179.11% |
| 5 Years | ₹519.00 | ₹2,226.70 | +329.04% |
Price Swings & Biggest Historical Drops
How much this stock typically fluctuates and its largest peak-to-bottom drops over 1 and 5 years.
Calendar-Year Historical Performance
Annual performance breakdown comparing first and last closing sessions of each calendar year.
| Calendar Year | Start Close | End Close | Annual Return | Trajectory Bar |
|---|---|---|---|---|
| CY 2026 | ₹2,026.20 | ₹2,226.70 | +9.9% | |
| CY 2025 | ₹1,614.50 | ₹2,035.20 | +26.1% | |
| CY 2024 | ₹855.65 | ₹1,609.10 | +88.1% | |
| CY 2023 | ₹427.70 | ₹853.95 | +99.7% | |
| CY 2022 | ₹525.25 | ₹424.15 | -19.3% | |
| CY 2021 | ₹519.00 | ₹528.55 | +1.8% |
Historical Investment Simulator
Factual simulation of past returns in GLENMARK PHARMACEUTICALS (GLENMARK) using real recorded closing prices.
Corporate Actions & Distributions
Historical record of dividend payouts and share split adjustments for GLENMARK.
Dividend Distributions (1)
| Ex-Date | Dividend Amount |
|---|---|
| 31 Aug 2026 | ₹2.50 per share |
Stock Splits & Multipliers (0)
No stock split adjustments recorded.
Recent News & Official Exchange Announcements
Official exchange filings, order wins, and company updates. Click any announcement to see how it affects the business on the right.
Q4 results today: Asian Paints, IndiGo, IREDA, Glenmark Pharma - 131 companies to announce earnings on 29 May - Livemint
Q4 results today: Asian Paints, IndiGo, IREDA, Glenmark Pharma - 131 companies to announce earnings on 29 May Livemint
Glenmark Pharmaceuticals closes trading window ahead of Q2FY27 results - scanx.trade
Glenmark Pharmaceuticals closes trading window ahead of Q2FY27 results scanx.trade
Glenmark Pharmaceuticals Q2 FY27 Results Preview: What the Numbers Show So Far - Univest
Glenmark Pharmaceuticals Q2 FY27 Results Preview: What the Numbers Show So Far Univest
Glenmark Pharmaceuticals to Host Q1 FY27 Earnings Call on August 3 - scanx.trade
Glenmark Pharmaceuticals to Host Q1 FY27 Earnings Call on August 3 scanx.trade
We Think Glenmark Pharmaceuticals' (NSE:GLENMARK) Healthy Earnings Might Be Conservative - Simply Wall Street
We Think Glenmark Pharmaceuticals' (NSE:GLENMARK) Healthy Earnings Might Be Conservative Simply Wall Street
Why This Matters for the Business
Plain-English breakdown of how the selected announcement connects to revenue, costs, and business drivers.
Quarterly financial statements disclosed under statutory SEBI LODR Regulation 33.
- •Quarterly financial results disclosed under SEBI LODR Regulation 33
Volume throughput absorbs fixed manufacturing plant overheads, supporting operating EBITDA margins and cash generation across diversified indian equities units.
Continuous commercial tenders and capital expenditures lock in forward order book-to-bill expansion.
At-a-Glance Health & Momentum Check
Company filings and balance-sheet numbers show steady day-to-day operations with stable margins and working capital.
Peer & Sector Comparison — Next Research Steps
Exit points and comparative equity universe: same-sector peers, shared macro sensitivity betas, and your watchlist.
Common Questions About GLENMARK PHARMACEUTICALS (GLENMARK)
Key facts on GLENMARK share price, historical returns, valuation ratios, and past SIP performance.
What is the current share price and 52-week range of GLENMARK PHARMACEUTICALS (GLENMARK)?
As of 16 Oct 2026, the official closing share price of GLENMARK PHARMACEUTICALS (GLENMARK) on NSE/BSE is ₹2,226.70 (-1.06% vs the previous close). Over the past 52 weeks, GLENMARK has traded between a low of ₹1,810.40 and a high of ₹2,515.00, with a reported market capitalization of ₹64,714.12 Cr.
What are the historical returns of GLENMARK PHARMACEUTICALS (GLENMARK)?
Based on split-adjusted closing prices through 16 Oct 2026, GLENMARK PHARMACEUTICALS (GLENMARK) recorded the following trailing price returns: 1 Week: -2.89% (from ₹2,293.00 to ₹2,226.70); 15 Days: -4.47% (from ₹2,331.00 to ₹2,226.70); 1 Month: -7.61% (from ₹2,410.00 to ₹2,226.70); 3 Months: -2.63% (from ₹2,286.90 to ₹2,226.70); 6 Months: -1.01% (from ₹2,249.50 to ₹2,226.70); 1 Year: +19.43% (from ₹1,864.40 to ₹2,226.70); 3 Years: +179.11% (from ₹797.80 to ₹2,226.70); 5 Years: +329.04% (from ₹519.00 to ₹2,226.70). Past performance reflects historical exchange records and does not predict future returns.
What is the P/E ratio, P/B ratio, and dividend yield of GLENMARK PHARMACEUTICALS (GLENMARK)?
GLENMARK PHARMACEUTICALS (GLENMARK) currently trades at a trailing Price-to-Earnings (P/E) ratio of 36.0x, a Price-to-Book (P/B) ratio of 6.2x, and a trailing 12-month dividend yield of 0.11%. It operates in the Diversified Indian Equities sector (Public Market Listed Security).
How much would a past lump-sum or monthly SIP investment in GLENMARK have grown?
Based on historical closing prices for GLENMARK PHARMACEUTICALS (GLENMARK): A one-time lump-sum investment of ₹1,00,000.00 held for 5 years would be worth ₹4,29,036.60 (+329.0% total return, 33.9% CAGR), while a monthly SIP of ₹10,000.00 over 5 years (total invested: ₹6,10,000.00) would be worth ₹17,12,162.78 (+180.7% absolute return). You can test custom amounts and holding periods in the interactive calculator above.
Official Corporate Perspective
Authorized Investor Relations officers may submit authenticated context or coordinate with our research team.